Robert Bell

Robert Bell

Company: Ascidian Therapeutics

Job title: Senior Vice President & Head of Research


Panel Discussion: Contesting the Viability of Viral Vectors for Gene Editing Delivery 9:45 am

Considering the off-target editing and immunogenicity of viral vectors and whether these bottlenecks are solvable Discussing the viability and reliability of self-inactivating viral vectors Understanding the effects of random incorporation of viral genetic components into the genome and continued expression of the gene editorRead more

day: Day Two

Optimizing Ocular Delivery to Accelerate In Vivo Therapy into the Clinic for Rare Retinal Disorders 2:45 pm

Assessing strategies to advance ocular gene editing delivery Understanding how the engineering differentiates from systemic delivery Addressing safety concernsRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.